최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기KJWHN : Korean journal of women health nursing, v.19 no.4, 2013년, pp.201 - 210
정주현 (서울아산병원) , 노주희 (울산대학교 간호학과) , 김기숙 (서울아산병원) , 이영은 (서울아산병원) , 유선영 (서울아산병원) , 이현주 (서울아산병원) , 심유미 (서울아산병원) , 이영선 (서울아산병원)
Purpose: The purpose of this study was to identify chemotherapy induced peripheral neuropathy, quality of life of patients with gynecologic cancer. Methods: This was a cross-sectional survey design. We collected 130 patients with gynecologic cancer. They complete a self reported questionnaire includ...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
말초신경병증의 운동 및 감각 신경 관련 증상과 자율신경 관련 증상은 무엇인가? | 말초신경병증은 말초신경섬유의 손상, 염증, 퇴화작용으로 인하여 운동, 감각, 자율 신경이 손상되어 나타나는 증상을 말한다(Yabro, Frogge, & Goodman, 2004). 운동, 감각 신경 관련 증상은 손가락, 발가락의 저림(tingling), 둔한 느낌(numbness), 타는 듯한 느낌(burning), 찌르는 느낌(stabbing), 따끔거림(pricking) 등이며 자율신경 관련 증상은 변비, 기립성 저혈압, 요실금 등이다(Smith, Beck, & Cohen, 2008). 이러한 증상은 급성으로 나타나 항암화학요법 종료 후 회복되기도 하지만 통증으로 느껴질 정도로 악화될 수 있고(Sweeney, 2002) 일부는 비가역적으로 몇 년 동안 지속되기도 한다(Wickham, 2007). | |
부인암의 치료에 주로 사용되는 항암제는 무엇인가? | 부인암의 치료에 주로 사용되는 항암제는 파클리탁셀, 카보플라틴, 시스플라틴 등으로 강한 항암작용을 가지고 있으나 저용량이더라도 반복적으로 투여할 경우 신경학적 독성이 문제가 되어(Calhoun et al., 2003) 90% 이상에서 말초신경병증이 발생된다(Viens et al. | |
말초신경병증이란 무엇인가? | 말초신경병증은 말초신경섬유의 손상, 염증, 퇴화작용으로 인하여 운동, 감각, 자율 신경이 손상되어 나타나는 증상을 말한다(Yabro, Frogge, & Goodman, 2004). 운동, 감각 신경 관련 증상은 손가락, 발가락의 저림(tingling), 둔한 느낌(numbness), 타는 듯한 느낌(burning), 찌르는 느낌(stabbing), 따끔거림(pricking) 등이며 자율신경 관련 증상은 변비, 기립성 저혈압, 요실금 등이다(Smith, Beck, & Cohen, 2008). |
Bakitas, M. A. (2007). Background noise: The experience of chemotherapy- induced peripheral neuropathy. Nursing Research, 56, 323-331. http://dx.doi.org/10.1097/01.nnr.0000 289503.22414.79
Bartlett, J. E., Kotrlik, J. W., & Higgins, C. C. (2001). Organizational research: Determining appropriate sample size in survey research. Information Technology, Learning, and Performance Journal, 19, 43-50.
Berek, J. S. (2007). Berek & Novak's Gynecology (14ed.). Philadelphia: Lippincott.
Calhoun, E. A., Welshman, E. E., Chang, C. H., Lurain, J. R., Fishman, D. A., Hunt, T. L., et al. (2003). Psychometric evaluation of functional assessment of cancer therapy/gynecologic oncology group-neurotoxicity(FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. International Journal of Gynecologic Oncology, 13, 741-748.
Cella, D. (1997). Manual of the functional assessment of chronic illness therapy (FACIT) measurement system. Evanston, IL: Center on outcomes, research and education (CORE), Evanston Northwestern Healthcare and Northwestern University.
Hausheer, F. H., Schilsky, R. L., Bain, S., Berghorn, E. J., & Lieberman, F. (2006). Diagnosis, management, and evaluation of chemotherapy induced peripheral neuropathy. Seminars in Oncology, 33, 15-49.
Kaley, T. J., & Deangelis, L. M. (2009). Therapy of chemotherapyinduced peripheral neuropathy. British Journal of Haematology, 145, 3-14. http://dx.doi.org/10.1111/j.1365-2141.2008. 07558.x
Kim, H. M. (2012). Symptoms and relief therapy related to chemotherapy induced peripheral neuropathy in patients with cancer. Unpublished master's thesis, Keimyoung University, Daegu.
Kiser, D. W., Greer, T. B., Wilmoth, M. C., Dmochowski, J., & Naumann, R. W. (2010). Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: Patient reports and provider assessments. Oncology Nursing Forum, 37, 758-764. http://dx.doi.org/10.1188/10.ONF.758-764
Long, H. J., Monk, B. J., Huang, H. Q., Grendys, E. C., Mc- Meekin, D. S., Sorosky, J., et al. (2006). Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A gynecologic oncology group study. Gynecologic Oncology, 100, 537-543.
Mantyh, P. W. (2006). Cancer pain and its impact on diagnosis, survival and quality of life. Nature Reviews Neuroscience, 7, 797-809.
Pan, Y., & Kao, M. S. (2007). Discordance of clinical symptoms and electrophysiologic findings in taxane plus platinum-induced neuropathy. International Journal of Gynecological Cancer, 17, 394-397. http://dx.doi.org/10.1111/j.1525-1438. 2006.00766.x
Rao, R. D., Michalak, J. C., Sloan, J. A., Loprinzi, C. L., Soori, G. S., Nikcevich, D. A., et al. (2007). Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, cross-over trial. Cancer, 110, 2110-2118. http://dx. doi.org/10.1002/cncr.23008
Smith, E. L., Whedon, M. B., & Bookbinder, M. (2002). Quality improvement of painful peripheral neuropathy. Seminars in Oncology Nursing, 18, 36-43.
Smith, E. M., Beck, S. L., & Cohen, J. (2008). The total neuropathy score: A tool for measuring chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum, 35, 96-102. http://dx.doi.org/10.1188/08.ONF.96-102
Statistics Korea. (2010). Cancer occurrence ratio in Korea women. Retrieved July, 15, 2013, from http://kosis.kr/wnsearch/ totalSearch.jsp
Sweeney, C. W. (2002). Understanding peripheral neuropathy in patients with cancer: Background and patients assessment. Clinical Journal of Oncology Nursing, 6, 163-166.
Tofthagen, C. (2010). Patient perceptions associated with chemotherapy- induced peripheral neuropathy. Clinical Journal of Oncology Nursing, 14, E22-E28. http://dx.doi.org/10.1188/ 10.CJON.E22-E28
Tofthagen, C., McAllister, R. D., & McMillan, S. C. (2011). Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clinical Journal of Oncology Nursing, 15 , 182-188. http://dx.doi.org/10.1188/11.CJON.182-188
Verstappen, C. C., Heimans, J. J., Hoekman, K., & Postma, T. J. (2003). Neurotoxic complication of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs, 63, 1549-1563.
Viens, P., Petit, T., Yovine, A., Bougnoux, P., Deplanque, G., Cottu, P. H., et al. (2006). A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Annuals of Oncology, 17, 429- 436. http://dx.doi.org/10.1093/annonc/mdj097
Wickham, R. (2007). Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing, 11 , 361-376.
Wolf, S., Barton, D., Kottschade, L., Grothey, A., & Loprinzi, C. (2008). Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. European Journal of Cancer, 44, 1507-1515. http://dx.doi.org/10.1016/j.ejca.2008. 04.018
Yarbro, C. H., Frogge, M. H., & Goodman, M. (2004). Cancer symptom management (3rd ed.). Boston: Jones and Bartlett.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.